S&P 500   3,660.13 (-0.06%)
DOW   29,794.29 (-0.10%)
QQQ   303.66 (+0.07%)
AAPL   123.03 (+0.25%)
MSFT   214.08 (-0.99%)
FB   288.02 (+0.51%)
GOOGL   1,824.13 (+1.60%)
AMZN   3,209.37 (-0.33%)
TSLA   561.14 (-4.04%)
NVDA   542.20 (+1.23%)
BABA   261.72 (-0.87%)
CGC   28.43 (+6.68%)
GE   10.36 (+2.07%)
MU   68.43 (+2.01%)
AMD   93.86 (+1.33%)
T   28.94 (+0.24%)
NIO   46.52 (+2.56%)
F   9.18 (-0.65%)
ACB   11.25 (+15.38%)
NFLX   502.75 (-0.36%)
BA   218.96 (+2.79%)
GILD   61.17 (+0.08%)
DIS   152.42 (+1.99%)
S&P 500   3,660.13 (-0.06%)
DOW   29,794.29 (-0.10%)
QQQ   303.66 (+0.07%)
AAPL   123.03 (+0.25%)
MSFT   214.08 (-0.99%)
FB   288.02 (+0.51%)
GOOGL   1,824.13 (+1.60%)
AMZN   3,209.37 (-0.33%)
TSLA   561.14 (-4.04%)
NVDA   542.20 (+1.23%)
BABA   261.72 (-0.87%)
CGC   28.43 (+6.68%)
GE   10.36 (+2.07%)
MU   68.43 (+2.01%)
AMD   93.86 (+1.33%)
T   28.94 (+0.24%)
NIO   46.52 (+2.56%)
F   9.18 (-0.65%)
ACB   11.25 (+15.38%)
NFLX   502.75 (-0.36%)
BA   218.96 (+2.79%)
GILD   61.17 (+0.08%)
DIS   152.42 (+1.99%)
S&P 500   3,660.13 (-0.06%)
DOW   29,794.29 (-0.10%)
QQQ   303.66 (+0.07%)
AAPL   123.03 (+0.25%)
MSFT   214.08 (-0.99%)
FB   288.02 (+0.51%)
GOOGL   1,824.13 (+1.60%)
AMZN   3,209.37 (-0.33%)
TSLA   561.14 (-4.04%)
NVDA   542.20 (+1.23%)
BABA   261.72 (-0.87%)
CGC   28.43 (+6.68%)
GE   10.36 (+2.07%)
MU   68.43 (+2.01%)
AMD   93.86 (+1.33%)
T   28.94 (+0.24%)
NIO   46.52 (+2.56%)
F   9.18 (-0.65%)
ACB   11.25 (+15.38%)
NFLX   502.75 (-0.36%)
BA   218.96 (+2.79%)
GILD   61.17 (+0.08%)
DIS   152.42 (+1.99%)
S&P 500   3,660.13 (-0.06%)
DOW   29,794.29 (-0.10%)
QQQ   303.66 (+0.07%)
AAPL   123.03 (+0.25%)
MSFT   214.08 (-0.99%)
FB   288.02 (+0.51%)
GOOGL   1,824.13 (+1.60%)
AMZN   3,209.37 (-0.33%)
TSLA   561.14 (-4.04%)
NVDA   542.20 (+1.23%)
BABA   261.72 (-0.87%)
CGC   28.43 (+6.68%)
GE   10.36 (+2.07%)
MU   68.43 (+2.01%)
AMD   93.86 (+1.33%)
T   28.94 (+0.24%)
NIO   46.52 (+2.56%)
F   9.18 (-0.65%)
ACB   11.25 (+15.38%)
NFLX   502.75 (-0.36%)
BA   218.96 (+2.79%)
GILD   61.17 (+0.08%)
DIS   152.42 (+1.99%)
Log in
ARCA:OGEN

Oragenics Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume2.75 million shs
Market Capitalization$28.79 million
P/E RatioN/A
Dividend YieldN/A
Beta0.75
Oragenics, Inc. develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring compound for use in weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against dental caries, or tooth decay. Oragenics, Inc. has collaboration agreements with Precigen, Inc. and its subsidiary, Intrexon Actobiotics NV to develop AG013; and a license agreement with LPThera LLC to develop LPT3-04. It also has a process development and drug substance manufacturing agreement with Avid Bioservices, Inc. for coronavirus vaccine. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.13 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone813 286 7900
Employees7

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.23 per share

Profitability

Net Income$-15,570,000.00

Miscellaneous

Market Cap$28.79 million
Next Earnings DateN/A
OptionableNot Optionable
30 days | 90 days | 365 days | Advanced Chart

Receive OGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for OGEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Oragenics (ARCA:OGEN) Frequently Asked Questions

What stocks does MarketBeat like better than Oragenics?

Wall Street analysts have given Oragenics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Oragenics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Oragenics' key competitors?

Who are Oragenics' key executives?

Oragenics' management team includes the following people:
  • Dr. Alan F. Joslyn, Pres, CEO & Director (Age 61, Pay $488.39k)
  • Mr. Michael O. Sullivan CPA, CFO, Sec. & Treasurer (Age 64, Pay $313.31k)
  • Dr. Martin Handfield, Sr. VP of Discovery Research (Age 49, Pay $244.92k)
  • Dr. Raman Bedi, Chairman of International Scientific Advisory Board and Sr. Consultant

What is Oragenics' stock symbol?

Oragenics trades on the ARCA under the ticker symbol "OGEN."

How do I buy shares of Oragenics?

Shares of OGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

How big of a company is Oragenics?

Oragenics has a market capitalization of $0.00. The company earns $-15,570,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. Oragenics employs 7 workers across the globe.

What is Oragenics' official website?

The official website for Oragenics is www.oragenics.com.

How can I contact Oragenics?

Oragenics' mailing address is 4902 EISENHOWER BLVD SUITE 125, TAMPA FL, 33634. The company can be reached via phone at 813 286 7900 or via email at [email protected]

This page was last updated on 12/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.